FDA reviews Sanofi's multiple myeloma drug isatuximab

The FDA has begun its review of Sanofi’s multiple myeloma drug isatuximab, as the French pharma prepares for a tussle with Johnson & Johnson’s blockbuster Darzalex.

FDA clears Karyopharm’s myeloma drug despite advisory panel ...

Janssen to develop Darzalex successor with Genmab

Janssen has signed a licence and option deal with Denmark’s Genmab to develop a next-generation drug that it hopes will outperform its already-marketed Darzalex in multiple myeloma, and oth

EU regulators to fast-track Janssen's multiple myeloma CAR-T

European regulators are to hasten development of Janssen’s CAR-T therapy for patients with multiple myeloma, after promising early-stage trial results.

GSK mulls filings for multiple myeloma drug

GlaxoSmithKline has announced more data making the case for its multiple myeloma antibody-drug conjugate GSK2857916, confirming that almost two thirds of patients responded to the drug afte

Question marks over AbbVie/Roche's venetoclax after safety s...

AbbVie and Roche have stopped recruiting patients for all multiple myeloma trials involving the drug venetoclax after a higher proportion of deaths was observed in patients receiving it tha